273 related articles for article (PubMed ID: 27078747)
21. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
22. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.
Truelove E; Fielding AK; Hunt BJ
Leukemia; 2013 Mar; 27(3):553-9. PubMed ID: 23099335
[TBL] [Abstract][Full Text] [Related]
23. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study.
Rozen L; Noubouossie D; Dedeken L; Huybrechts S; Lê PQ; Ferster A; Demulder A
Pediatr Blood Cancer; 2017 Feb; 64(2):294-301. PubMed ID: 27605400
[TBL] [Abstract][Full Text] [Related]
24. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
[TBL] [Abstract][Full Text] [Related]
25. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
Appel IM; Hop WC; Pieters R
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
[TBL] [Abstract][Full Text] [Related]
26. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
27. Thrombosis in children with acute lymphoblastic leukemia treated at a tertiary care center in Lebanon: revisiting the role of predictive models.
Al-Aridi C; Abboud MR; Saab R; Eid D; Jeha S; Chan AK; Muwakkit SA
Pediatr Hematol Oncol; 2011 Nov; 28(8):676-81. PubMed ID: 21787123
[TBL] [Abstract][Full Text] [Related]
28. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
29. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043
[TBL] [Abstract][Full Text] [Related]
30. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Duarte X; Esteves S; Neto AM; Pereira F
Br J Haematol; 2016 Jul; 174(2):280-91. PubMed ID: 27018199
[TBL] [Abstract][Full Text] [Related]
32. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
33. [Successful readministration of L-asparaginase after development of severe hypertriglyceridemia in a young adult with T-cell acute lymphoblastic leukemia].
Watanabe K; Yoshifuji K; Ohkawa R; Tozuka M; Miura O; Arai A
Rinsho Ketsueki; 2018; 59(12):2555-2560. PubMed ID: 30626788
[TBL] [Abstract][Full Text] [Related]
34. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
35. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
36. Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
Malhotra P; Jain S; Kapoor G
J Pediatr Hematol Oncol; 2018 Oct; 40(7):e450-e453. PubMed ID: 29554021
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.
Al-Nawakil C; Willems L; Mauprivez C; Laffy B; Benm'rad M; Tamburini J; Fontaine H; Sogni P; Terris B; Bouscary D; Moachon L
Leuk Lymphoma; 2014 Jul; 55(7):1670-4. PubMed ID: 24090500
[No Abstract] [Full Text] [Related]
38. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Tong WH; Pieters R; de Groot-Kruseman HA; Hop WC; Boos J; Tissing WJ; van der Sluis IM
Haematologica; 2014 Nov; 99(11):1716-21. PubMed ID: 25150254
[TBL] [Abstract][Full Text] [Related]
39. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.
Zaunschirm A; Muntean W
Pediatr Hematol Oncol; 1986; 3(1):19-25. PubMed ID: 3153215
[TBL] [Abstract][Full Text] [Related]
40. Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy.
Imamura T; Morimoto A; Kato R; Izumi M; Murakami A; Matuo S; Kiyosawa N; Kano G; Yoshioka H; Sugimoto T; Imashuku S
Leuk Lymphoma; 2005 May; 46(5):729-35. PubMed ID: 16019511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
